VXLLF (Vaxil Bio) Current Ratio: 17.08 (As of Mar. 2026) — 326% Above Median


VXLLF Vaxil Bio Ltd VXLLF
38 GF Score
Price $0.02
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio Current Ratio?

Vaxil Bio VXLLF -85.27% 38 Current Ratio is 17.08 as of Mar. 2026, which is 326% above its 10-year median of 4.01. GuruFocus rates VXLLF with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Vaxil Bio ranks better than 88.98% on this metric.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vaxil Bio's current ratio for the quarter that ended in Mar. 2026 was 17.08.

Vaxil Bio has a current ratio of 17.08. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Vaxil Bio's Current Ratio or its related term are showing as below:

VXLLF' s Current Ratio Range Over the Past 10 Years
Min: 0.14   Med: 4.01   Max: 137
Current: 16.92

During the past 13 years, Vaxil Bio's highest Current Ratio was 137.00. The lowest was 0.14. And the median was 4.01.

VXLLF's Current Ratio is ranked better than
88.98% of 1416 companies
in the Biotechnology industry
Industry Median: 3.885 vs VXLLF: 16.92

Vaxil Bio  (OTCPK:VXLLF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Vaxil Bio Current Ratio Related Terms


Vaxil Bio Current Ratio Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio Current Ratio Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.90 3.81 11.54 42.83 124.25

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.00 114.25 72.67 124.25 17.08

VXLLF vs VRTX, REGN, ALNY: Current Ratio Comparison

For the Biotechnology subindustry, Vaxil Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxil Bio Current Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxil Bio's Current Ratio distribution charts can be found below:

* The bar in red indicates where Vaxil Bio's Current Ratio falls into.


VXLLF
38GF Score
Vaxil Bio Ltd VXLLF
Current Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Vaxil Bio's Current Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Current Ratio (A: Dec. 2025 )=Total Current Assets (A: Dec. 2025 )/Total Current Liabilities (A: Dec. 2025 )
=0.497/0.004
=124.25

Vaxil Bio's Current Ratio for the quarter that ended in Mar. 2026 is calculated as

Current Ratio (Q: Mar. 2026 )=Total Current Assets (Q: Mar. 2026 )/Total Current Liabilities (Q: Mar. 2026 )
=0.444/0.026
=17.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 17.08 mean?
Vaxil Bio (VXLLF) has a Current Ratio of 17.08 as of Mar. 2026. This is 326% above median its historical median of 4.01. Over the past decade, Vaxil Bio's Current Ratio has ranged from 0.14 to 137.00. According to the industry distribution chart, Vaxil Bio ranks #156 out of 1416 companies in the Biotechnology industry, placing it in the top 11%.
Is Vaxil Bio's Current Ratio too high?
Vaxil Bio's current Current Ratio of 17.08 is 326% above median its 10-year median of 4.01. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 137.00. The Biotechnology industry median Current Ratio is 3.89. Vaxil Bio's value of 17.08 is 339.6% above this industry median. Based on the distribution chart, Vaxil Bio ranks #156 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vaxil Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vaxil Bio ranks #156 out of 1416 companies for Current Ratio. This places Vaxil Bio in the top 11% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Vaxil Bio's value of 17.08 is 339.6% above this benchmark. Historically, Vaxil Bio's own Current Ratio has ranged from 0.14 to 137.00 over the past decade. While the company's 10-year median is 4.01 vs. the industry median of 3.89, Vaxil Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxil Bio's current Current Ratio of 17.08 is 339.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxil Bio's current Current Ratio is 17.08, which is 326% above median its own 10-year median of 4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current Current Ratio of 17.08. The current Current Ratio is 17.08, which is 326% above median its 10-year median of 4.01 and 339.6% above the Biotechnology industry median of 3.89. Vaxil Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current Current Ratio is 17.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
38GF Score

Get the complete analysis for VXLLF

Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price